November 30, 2022

Conagen develops high-purity non-GMO sulforaphane by bioconversion

Commercial production is underway for 2023.

Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen, announced the development of its 99% high-purity sulforaphane. Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023. Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.

“As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realize many of its promising health benefits,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “We’re looking forward to expanding the nutritional market by commercializing sulforaphane in 2023.”

Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition. With biotechnology and biomanufacturing advancements, much like Conagen’s bioconversion technology, more nutritional offerings are produced at a high-quality and global scale.

Sulforaphane is found in cruciferous vegetables such as arugula, bok choy, broccoli, Brussels sprouts, cabbage, kale, radish, and more. In these vegetables, the inactive form of glucoraphanin belongs to the glucosinolate family of plant compounds. The sulfur-rich sulforaphane is activated only when vegetables are chewed or chopped to release myrosinase, a class of enzymes that play a role in the defense response of plants.

“Through Conagen’s bioconversion technology, we’re uncovering the great potential in sulforaphane as a powerful active health ingredient for consumers who are personalizing nutrition to support health functions,” said Lippmeier. “We can make safe and high-quality nutritional ingredients from natural sources and offer it at a global-scale cost-competitively so that brands may pass on the good health and savings to their consumers.”

Conagen’s sulforaphane is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal. More research is emerging for understanding the optimistic effects on multiple health functions. As one example of many, biotechnology and biomanufacturing will continue to harness the power of biology and nature to develop and deliver solutions for better nutrition, health, and wellness. Conagen is expanding its sustainable, nutritional products portfolio to better humankind and the planet.

About Conagen
Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.

Attachments

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1-781-271-1588
ana.arakelian@conagen.com

GlobeNewswire Distribution ID 8705501

November 30, 2022

Amazon Deforestation in Brazil Remains Near 15-Year High

Deforestation in the Brazilian Amazon slowed slightly last year, a year after setting a 15-year high, according to closely watched numbers published Wednesday. The data was released by the National Institute for Space Research.

The agency’s Prodes monitoring system shows the rainforest lost an area roughly the size of Qatar, about 11,600 square kilometers in the 12 months from August 2021 to July 2022.

That is down 11% compared with the previous year, when more than 13,000 square kilometers were destroyed.

For more than a decade deforestation in the Brazilian Amazon declined dramatically and never rose back above 10,000 square kilometers. Then came the presidency of far-right President Jair Bolsonaro, beginning in January 2019.

This will be the last report published under Bolsonaro, who lost his reelection bid and will leave office January 1. But part of the destruction that took place on his watch will not appear until next year, including the key months from August to October 2022. A because it is the dry season.

An analysis of the new yearly data from Climate Observatory, a network of environmental groups, shows that in the four years of Bolsonaro’s leadership, deforestation rose 60% over the previous four years. That is the largest percentage rise under a presidency since satellite monitoring began in 1998.

In one state, Para, a fierce rate of destruction fell by 21% yet it was still the center of one-third of all Brazil’s Amazon forest loss. Part of the tree cutting and burning happens in areas that are ostensibly protected. One such area is Paru State Forest, where the nonprofit Amazon Institute of People and the Environment registered 2 square kilometers of deforestation in just October.

“In recent years, deforestation has reached protected areas where previously there was almost no destruction,” Jacqueline Pereira, a researcher with the Amazon Institute, told The Associated Press. “In Paru’s region, the destruction is driven by lease of land for soybean crops and cattle.”

Another critical area is the southern part of the state of Amazonas, the only state that increased deforestation in the most recent data, by 13% compared to the year before. It’s largely attributable to Bolsonaro’s push to pave about 400 kilometers of the only road that connects Manaus, home to 2.2 million people, with Brazil’s larger urban centers further south. Most Amazon deforestation occurs alongside roads where access is easier and land value is higher.

Researchers and environmentalists have blamed Bolsonaro’s policies for the surge in deforestation. The administration weakened environmental agencies and backed legislative measures to loosen land protections in the name of economic development, paired with a view of occupying a sparsely populated territory at any cost. This policy has emboldened land robbers and spurred more illegal mining.

Bolsonaro’s successor, leftist former President Luiz Inácio Lula da Silva, promised cheering crowds at the recent U.N. climate conference in Egypt to end all deforestation in the country by 2030.

“There will be no climate security if the Amazon isn’t protected,” he said.

The last time da Silva was president, from 2003 to 2010, deforestation fell sharply. On the other hand, he backed initiatives that set in motion destruction in the long run, such as the construction of the mammoth Belo Monte hydroelectric dam and generous loans to the beef industry. Chopping down forest for pasture is the primary driver of deforestation.

The Amazon rainforest, which covers an area twice the size of India, acts as a buffer against climate change by absorbing large amounts of carbon dioxide. It’s also the most biodiverse forest in the world, and the home of tribes that have lived in the forest for thousands of years, some of them living in isolation.

“If da Silva wants to decrease forest destruction by 2023, he must have zero tolerance for environmental crime from Day One of his administration. That includes holding accountable those who sabotaged environmental governance in the country while in office over the past four years,” said Marcio Astrini, executive secretary of the Climate Observatory.

Source: Voice of America

November 30, 2022

This HIV Prevention Drug Could Change the Game

the drug, has not officially announced what it will cost in low- and middle-income countries, but it is expected to be much lower. Some aid groups have indicated that ViiV will offer the drug at $250 per year.

“The problem is that actually that won’t be really affordable for countries who need to roll it out and scale up,” said Jessica Burry, a pharmacist with humanitarian group Doctors without Borders.

PrEP pills cost about $54 per year, Warren said.

“The hope is that early in 2023, we can see a price point that is much closer to that 54 [dollars] than to the 250 [dollars],” he said. “Hopefully, in the $100 range per year.”

ViiV said it is working with the U.N.-backed Medicines Patent Pool to allow generic manufacturers to produce cabotegravir at a lower price for low- and middle-income countries.

ViiV said cabotegravir is more complicated to manufacture than most HIV drugs. No generic manufacturers have been selected yet. Once they are, it will take about three to five years before a generic version is on the market.

The company has filed for regulatory approval in 11 countries so far. Burry says there should be more.

“If they’re going to be the only supplier for the next four or five years until generics are available, then they really need to step up to the plate and actually file, register and get that drug available,” she said.

Demand for the drug is unclear. PrEP pills have been slow to catch on.

About 845,000 people in more than 50 countries took them in 2020, but the United Nations was aiming for 3 million by that time.

“We don’t have a ton of PrEP users, so if you’re ViiV, you’re looking at a very small market,” Warren said.

Warren said providers and advocates need to help grow that market. They need to do a better job connecting people at risk with programs that offer PrEP, he added.

“Some of the early PrEP programs began with us thinking that if you just bought the product, people would magically show up,” he said.

Warren hopes to change that as part of a coalition that includes ViiV, the Bill and Melinda Gates Foundation, the World Health Organization and others.

“There’s a huge effort in this coalition to bring in civil society from day one, and the communities that this product is meant to help and support,” he said.

The slow uptake means PrEP has not yet shown that it can make much of a real-world impact, Warren noted. He hopes to see research programs launch next year to find the best ways to reach the communities most at risk and lower infection rates.

“If we can’t show that in the next three years, then we don’t necessarily need all these generic manufacturers, because there will not be a market for this product,” he said.

Source: Voice of America

November 30, 2022

Malawi Launches Africa’s First Children’s Malaria Vaccine

Malawi and the World Health Organization are rolling out a new malaria vaccine for young children that backers say will reduce deaths from the mosquito-borne disease.

The RTSS vaccine was pilot tested on more than one million children in Ghana, Kenya and Malawi and recommended a year ago by the WHO. Despite a low effectiveness rate of 30%, the vaccine has raised hopes that some of the more than 400,000 people who die annually from malaria can be saved.

Malaria remains a huge public health problem in Malawi, with about one third of its 20 million people getting infected each year.

According to the ministry of health, the disease kills five Malawians every day, most of them children under the age of five or pregnant women who were not presented early enough for care.

The health ministry says the first phase of the vaccination campaign will target 330,000 children, who were not reached during vaccine trials.

The vaccine, sold by GlaxoSmithKline as Mosquirix, is meant for children under the age of five and requires four doses.

“Malaria is major problem in children. They are the ones at highest risk of dying,” said Dr. Charles Mwansambo, Malawi’s secretary for health. “That’s why even when we were doing the earlier studies, we found that once we get maximum benefit, we should target this age group. The main reason is that they are the ones that are most likely to die from malaria.”

Last year, the government launched a nationwide anti-malaria initiative known as Zero Malaria Starts with Me, aimed at eliminating the disease by 2030.

Mwansambo said the vaccine is a key part of that initiative.

“It actually prevents about 33 percent of deaths. Meaning that if you add the 33 to those that we can prevent using insecticide treated nets, if will also add on those [we can] prevent by indoor residual spraying, it [can] add up to something significant that will end up eliminating malaria,” he said.

However, the Bill and Melinda Gates Foundation, backers of the vaccine, have raised concerns about whether the vaccine is worth the cost.

In July, the Associated Press quoted Philip Welkhoff, director of malaria programs for the Gates Foundation, as saying the foundation will no longer offer direct financial support for the vaccine, although it will fund an alliance backing the vaccine.

He said Mosquirix has much lower efficacy than the foundation would like and that the vaccine is relatively expensive and logistically challenging to deliver.

Dr. Neema Kimambo, a WHO representative in Malawi, said the malaria vaccine itself is not a silver bullet but part of a combination of all interventions to fight the disease.

“Where it [vaccination] was done, we have seen how it has reduced under-five deaths and we believe that as we expand now, we are definitely to save more lives of children under five,” she said.

Maziko Matemba, a health activist and community health ambassador in Malawi, said he hopes the malaria vaccine efficacy will improve as time goes by.

“I have an example with COVID-19. When we had AstraZeneca, the efficacy when it started — as you know it was also a new vaccine — it was less that certain percentage and people said no it was less than this. But over time, we found that the efficacy has gone up,” Matemba said. “So we are monitoring the launch of this new vaccine with keen interest.

“I know that other partners are saying the worthiness of investment is not worth it, but looking at the way we are coming from, Malawi in particular, this could be one of the tools to prevent malaria.”

Besides WHO, other partners supporting Malawi in the fight against malaria include USAID, UNICEF, the Global Fund to Fight AIDS, Tuberculosis and Malaria and a global health nonprofit organization, PATH.

Source: Voice of America